ProfileGDS5678 / 1437902_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 97% 94% 97% 93% 98% 94% 94% 96% 96% 97% 90% 95% 95% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.2781297
GSM967853U87-EV human glioblastoma xenograft - Control 28.2316294
GSM967854U87-EV human glioblastoma xenograft - Control 39.5081697
GSM967855U87-EV human glioblastoma xenograft - Control 47.9456393
GSM967856U87-EV human glioblastoma xenograft - Control 510.013798
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.8760994
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7844194
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.9899196
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.851496
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.1860597
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1261490
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.6160595
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.3554395
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.0396794